Literature DB >> 20096987

Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: lymph-node mapping and identification of predictive factors for lymph-node status.

Christina Fotopoulou1, Konstantinos Savvatis, Robert Kraetschell, Joerg C Schefold, Werner Lichtenegger, Jalid Sehouli.   

Abstract

OBJECTIVE: To systematically assess the metastatic pattern of intermediate- and high-risk endometrial cancer in pelvic and para-aortic lymph-nodes and to evaluate risk factors for lymph-node metastases. STUDY
DESIGN: Between 01/2005 and 01/2009 62 consecutive patients with intermediate- and high-risk endometrial cancer who underwent a systematic surgical staging including pelvic and para-aortic lymphadenectomy were enrolled into this study. Patients' characteristics, histological findings, lymph-node localization and involvement, surgical morbidity and relapse data were analyzed. Univariate analysis was performed to define risk factors for lymph-node metastasis.
RESULTS: Of the 13 patients (21%) with positive lymph-nodes (N1), 8 (61.5%) had both pelvic and para-aortic lymph-nodes affected, 2 (15.4%) only para-aortic and 3 (23%) only pelvic lymph-node metastases. Overall, 54% of the N1-patients had positive lymph-nodes above the inferior mesenteric artery (IMA) to the level of the renal veins. Univariate analysis revealed lymph vascular space invasion (p-value: <0.001), vascular-space-invasion (p-value: <0.001) and incomplete tumor resection (p-value: 0.008) as significant risk factors for N1-status. Overall and progression-free survival was not significantly different between N1- and N0-patients.
CONCLUSIONS: Since the proportion of N1-endometrial cancer patients with positive para-aortic lymph-nodes is, at 76%, considerably high, and more than half of them have affected lymph-nodes above the IMA-level, lymphadenectomy for endometrial cancer should be extended up to the renal veins, when indicated. The therapeutic impact of systematic lymphadenectomy on overall and progression-free survival has still to be evaluated in future prospective randomized studies. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20096987     DOI: 10.1016/j.ejogrb.2009.12.021

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  9 in total

1.  Survival advantage of lymphadenectomy in endometrial cancer.

Authors:  Holm Eggemann; Tanja Ignatov; Katharina Kaiser; Elke Burger; Serban Dan Costa; Atanas Ignatov
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-08       Impact factor: 4.553

2.  Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer.

Authors:  Sanjeev Kumar; Karl C Podratz; Jamie N Bakkum-Gamez; Sean C Dowdy; Amy L Weaver; Michaela E McGree; William A Cliby; Gary L Keeney; Gillian Thomas; Andrea Mariani
Journal:  Gynecol Oncol       Date:  2013-10-09       Impact factor: 5.482

3.  Lymphadenectomy should be performed up to the renal vein in patients with intermediate-high risk endometrial cancer.

Authors:  Ismail Alay; Taner Turan; Isin Ureyen; Alper Karalok; Tolga Tasci; Ahmet Ozfuttu; M Faruk Kose; Gokhan Tulunay
Journal:  Pathol Oncol Res       Date:  2015-01-07       Impact factor: 3.201

4.  Surgical and systemic management of endometrial cancer: an international survey.

Authors:  Christina Fotopoulou; Robert Kraetschell; Sean Dowdy; Keiichi Fujiwara; Nobuo Yaegashi; Domenica Larusso; Antonio Casado; Sven Mahner; Thomas J Herzog; Sean Kehoe; Ignace Vergote; David Scott Miller; Christian Marth; Shingo Fujii; Jalid Sehouli
Journal:  Arch Gynecol Obstet       Date:  2014-10-15       Impact factor: 2.344

5.  Efficacy of contemporary chemotherapy in stage IIIC endometrial cancer: a histologic dichotomy.

Authors:  Jamie N Bakkum-Gamez; Andrea Mariani; Sean C Dowdy; Amy L Weaver; Michaela E McGree; Janice R Martin; Gary L Keeney; Aminah Jatoi; Bobbie S Gostout; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2014-01-14       Impact factor: 5.482

Review 6.  Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence.

Authors:  Giorgio Bogani; Sean C Dowdy; William A Cliby; Fabio Ghezzi; Diego Rossetti; Andrea Mariani
Journal:  J Obstet Gynaecol Res       Date:  2014-02       Impact factor: 1.730

7.  The effect of cell type on surgico-pathologic risk factors in endometrial cancer.

Authors:  Ahmet Taner Turan; Betül Dündar; Burcu Gündoğdu; Abdullah Boztosun; Nejat Ozgül; Nurettin Boran; Gökhan Tulunay; Ahmet Ozfuttu; Mehmet Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-03-01

8.  Contemporary clinical management of endometrial cancer.

Authors:  Helen E Dinkelspiel; Jason D Wright; Sharyn N Lewin; Thomas J Herzog
Journal:  Obstet Gynecol Int       Date:  2013-06-24

Review 9.  Current landscape and future perspective of sentinel node mapping in endometrial cancer.

Authors:  Giorgio Bogani; Francesco Raspagliesi; Umberto Leone Roberti Maggiore; Andrea Mariani
Journal:  J Gynecol Oncol       Date:  2018-11       Impact factor: 4.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.